Seven European healthtech scaleups profiled, including Spain's MiMARK Diagnostics and Anaconda Biomed

The story so far, in brief; the legwork, and the full article, stay with the original outlet.

A roundup of European healthtech scaleups, all members of the EIC Scaling Club, profiles companies working on diagnosis, devices and new therapies. Two are Spanish. MiMARK Diagnostics is developing molecular tests that look for disease biomarkers in gynaecological samples, mainly to detect endometrial cancer, where diagnosis can currently mean a biopsy or hysteroscopy. Barcelona-based Anaconda Biomed makes the ANA Funnel Catheter, a self-expanding, funnel-shaped device used in mechanical thrombectomy to pull clots out of blocked brain arteries after an acute ischaemic stroke. It works alongside existing thrombectomy tools, and the company secured $56 million in financing in September 2026.

The others come from across the continent. Bulgaria's Checkpoint Care combines wearables, a round-the-clock virtual care centre and AI for remote monitoring, and says it has supported more than 95,000 acute patients. Lithuania's Ligence automates the reading of cardiac ultrasound and received its second US FDA 510(k) clearance in April 2026. France's CorWave builds an implantable heart pump with a wave membrane instead of a rotor; its first patient, in Sydney in May 2025, went on to a heart transplant after 84 days of support. Iceland's Arctic Therapeutics, which raised a €26.5 million Series A in 2025, uses genetic data to target rare neurological diseases and dementia. Sweden's Asgard Therapeutics is trying to reprogram tumour cells so that they recruit the immune system against the cancer.

The EIC Scaling Club is funded by the EIC and run with partners including Bpifrance, IESE Business School and Tech.eu, which is a tidy arrangement for a list of companies to keep an eye on.